Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

Belly Fat Linked To Heart Failure Risk

WEDNESDAY, March 18, 2026 Want to figure out your heart health risk Look at your belly fat, not your body mass index, a new study says. Excess fat stored around

Meningitis Outbreak Tied to Students Leaves 2 Dead and 11 Sick in England

WEDNESDAY, March 18, 2026 Health officials in southern England are investigating a meningitis outbreak that has led to the deaths of two young people and sicken

Wastewater Surveillance Can Track Potential Colorectal Cancer Burden

Wastewater-based epidemiology is feasible as a community-level and population-level surveillance tool for colorectal cancer (CRC), according to a study publishe

Improved Survival But More Adverse Events Seen for Women With Cancer

Female cancer patients have increased survival but also have a higher risk for serious and adverse side effects from cancer treatment compared with men, accordi

PFOS, PFHA, Mono-Iso-Nonyl-Phthalate Can Predict Lung Cancer Mortality

A model composed of perfluorooctanesulfonic acid (PFOS), perfluoroheptanoic acid (PFHA), and the plasticizer mono-iso-nonyl-phthalate can predict lung cancer mo

Overall Cancer Incidence Not Higher With Medically Assisted Reproduction

Among women using medically assisted reproduction (MAR), the overall incidence of cancer was comparable to that of the general population, according to a study

Inulin, Physical Therapy-Supported Exercise Reduce Pain in Knee OA

For patients with knee osteoarthritis (OA), the prebiotic fiber inulin and physical therapy-supported exercise (PSE) produce meaningful reductions in pain, acco

Argo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE

SHANGHAI, CHINA and NEW YORK, USA-March 16, 2026 Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer Inc. (NYSE PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulves

EAU: 90-Day Mortality Rate 9.2 Percent for Emergency Hematuria

Ninety-day mortality is 9.2 percent for people presenting with emergency hematuria, with malignancy the underlying cause for 25 percent, according to a study pr

Popular Keywords